Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer's Disease


Por: Monge-Garcia, V, Garcia-Ayllon, M, Saez-Valero, J, Sanchez-Paya, J, Navarrete-Rueda, F, Manzanares-Robles, J, Gasparini-Berenguer, R, Romero-Lorenzo, R, Cortes-Gomez, M and Monge-Argiles, J

Publicada: 1 sep 2021 Ahead of Print: 10 sep 2021
Resumen:
Background: Alzheimer's disease (AD) is characterized by the presence of beta-amyloid plaques and neurofibrillary tangles, while Lewy body dementia (LBD) is characterized by alpha-synuclein (alpha-syn) inclusions. Some authors examine alpha-syn protein in the neurodegeneration process of AD and propose to consider cerebrospinal fluid (CSF) alpha-syn as a possible additional biomarker to the so-called "core" of AD. Objective: To determine whether there is a correlation between alpha-syn levels and "core" AD biomarkers in patients with mild cognitive impairment (MCI). Materials and methods: In total, 81 patients in the early stages of MCI were selected from the outpatient dementia consultation in Alicante General Hospital. Using a cross-sectional case-control design, patients were analyzed in four groups: stable MCI (MCIs; n = 25), MCI due to AD (MCI-AD; n = 32), MCI due to LBD (MCI-LBD; n = 24) and a control group of patients with acute or chronic headache (Ctrl; n = 18). Correlation between CSF protein levels in the different groups was assessed by the Rho Spearman test. Results: We found positive correlations between T-tau protein and alpha-syn (rho = 0.418; p value < 0.05) and p-tau(181p) and alpha-syn (rho = 0.571; p value < 0.05) exclusively in the MCI-AD group. Conclusion: The correlation found between alpha-syn and tau proteins in the first stages of AD support the involvement of alpha-syn in the pathogenesis of AD. This result may have clinical and diagnostic implications, as well as help to apply the new concept of "precision medicine" in patients with MCI.

Direcciones
Monge-Garcia, V: Univ Gen Hosp Alicante, Rehabil Serv, Alicante 03010, Spain
Garcia-Ayllon, MS: Univ Gen Hosp Elche, FISABIO, Res Unit, Elche 03456, Spain; Miguel Hernandez CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain; Ctr Invest Biomed Red Enfermedades Neurodegenerat, Alicante 03550, Spain
Saez-Valero, J: Univ Gen Hosp Elche, FISABIO, Res Unit, Elche 03456, Spain; Miguel Hernandez CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain; Inst Sanit & Biomed Res Alicante ISABIAL, Alicante 03010, Spain
Sanchez-Paya, J: Inst Sanit & Biomed Res Alicante ISABIAL, Alicante 03010, Spain; Univ Gen Hosp Alicante, Prevent Med Serv, Alicante 03010, Spain
Navarrete-Rueda, F: Miguel Hernandez CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain
Manzanares-Robles, J: Miguel Hernandez CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain
Gasparini-Berenguer, R: Univ Gen Hosp Alicante, Neurol Dept, Alicante 03010, Spain
Romero-Lorenzo, R: Univ Gen Hosp Alicante, Neurol Dept, Alicante 03010, Spain
Cortes-Gomez, MA: Miguel Hernandez CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain
Monge-Argiles, JA: Inst Sanit & Biomed Res Alicante ISABIAL, Alicante 03010, Spain; Univ Gen Hosp Alicante, Neurol Dept, Alicante 03010, Spain
ISSN: 16489144





MEDICINA-LITHUANIA
Editorial
Kauno Medicinos Universitetas, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Lituania
Tipo de documento: Article
Volumen: 57 Número: 9
Páginas:
WOS Id: 000699869600001
ID de PubMed: 34577877
imagen Green Published, gold

FULL TEXT

imagen Accepted Version
No Accesible

MÉTRICAS